Cingulate Reports First Quarter 2024 Financial Results and Provides Clinical and Business Update

May 8, 2024

https://www.globenewswire.com/news-release/2024/05/08/2877649/0/en/Cingulate-Reports-First-Quarter-2024-Financial-Results-and-Provides-Clinical-and-Business-Update.html

CTx-1301 on track to file for Marketing Approval with FDA in 1H 2025

Increase of $10 Million in Stockholders’ Equity

KANSAS CITY, Kan., May 08, 2024 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ:CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and advance a pipeline of next-generation pharmaceutical products, today announced its financial results for the three months ended March 31, 2024, and provided a clinical and business update.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.